news flash·2025-04-24 09:57Core Viewpoint - The approval of Ivenoxin (enoxaparin sodium injection) by the South African Health Products Regulatory Authority is expected to enhance the sales of the product in the South African market and increase the company's global market share [1] Company Summary - The company, Haiprui (002399), announced that its wholly-owned subsidiary, Tiandao Pharmaceutical, has received the approval notification for enoxaparin sodium injection [1] - The product is available in various specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg, and 1.0ml:100mg [1] - The indications for the product include thrombosis prevention before and after surgery, reduction of thrombotic risk in acute diseases, and treatment of deep vein thrombosis [1] - The license for the product is valid for five years [1] Industry Summary - The approval is anticipated to boost the company's enoxaparin sodium formulation sales in South Africa, contributing positively to its market presence [1]